Business Wire·Aug 11, 2026, 4:00 PM ET

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics reported financial results for the second quarter ended June 30, 2026, with a net loss of $8.2 million.
R&D expenses increased to $6.0 million from $3.2 million in the same period last year due to higher CMC, clinical trial, \& research study costs.
G\&A expenses decreased to $2.9 million from $4.0 million in the prior year period due to reduced professional services \& personnel costs.
The company holds $79.9 million in cash, cash equivalents, \& investments, projecting operations to be sustained into 2029.
Phase 2 start-up activities are expanding for the global trial of oral epetraborole in polycythemia vera (EBO-PV-201), with an IND filing expected in Q3 2026.
Enrollment is ongoing for an investigator-initiated Phase 2 trial of epetraborole in M. abscessus lung disease, with topline results anticipated in late 2027.
Positive non-human primate efficacy data \& favorable Phase 1 safety results support the planned Phase 2 initiation of AN2-502998 for chronic Chagas disease by year-end.
The company declared a development candidate for solid tumors earlier in 2026 \& expects to advance a second candidate by the end of 2026.
Three Phase 2 programs are targeted to be underway by the end of 2026, focusing on polycythemia vera, M. abscessus lung disease, \& chronic Chagas disease.
The boron chemistry platform aims to deliver differentiated therapies across hematologic diseases, infectious diseases, \& oncology.